0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%

Heart Test Laboratories Inc. Common Stock

Healthcare US HSCS

3.41USD
-0.35(9.31%)

Last update at 2024-12-19T18:46:00Z

Day Range

3.323.75
LowHigh

52 Week Range

5.21112.00
LowHigh

Fundamentals

  • Previous Close 3.76
  • Market Cap4.20M
  • Volume44578
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.99912M
  • Revenue TTM0.02M
  • Revenue Per Share TTM0.09
  • Gross Profit TTM 0.00235M
  • Diluted EPS TTM-36.69

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Income before tax -6.35429M -4.82826M -2.45217M -3.81112M
Minority interest - - - -
Net income -490.85429M -4.57806M -2.58117M -3.83382M
Selling general administrative 3.65M 1.71M 0.87M 1.80M
Selling and marketing expenses - - - -
Gross profit 0.00235M 0.00648M 0.01M 0.02M
Reconciled depreciation 0.03M 0.03M 0.03M 0.06M
Ebit -6.11296M -4.70940M -2.56813M -3.81818M
Ebitda -6.08420M -4.68027M -2.53797M -3.73446M
Depreciation and amortization 0.03M 0.03M 0.03M 0.08M
Non operating income net other - - - -
Operating income -6.11296M -4.70940M -2.56813M -3.81818M
Other operating expenses 6.12M 4.72M 2.59M 3.88M
Interest expense 0.24M 0.37M 0.13M 0.00281M
Tax provision - - - -
Interest income - - - -
Net interest income -0.24317M -0.37162M -0.13245M -0.00281M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 484.50M -0.25020M 0.13M 0.02M
Total revenue 0.00515M 0.01M 0.03M 0.06M
Total operating expenses 6.12M 4.72M 2.58M 3.84M
Cost of revenue 0.00280M 0.00789M 0.01M 0.05M
Total other income expense net -0.24133M -0.11886M 0.12M 0.00707M
Discontinued operations - - - -
Net income from continuing ops -6.35429M -4.82826M -2.45217M -3.81112M
Net income applicable to common shares -6.35429M -4.82826M -2.45217M -3.81112M
Preferred stock and other adjustments - - - -
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Total assets 3.29M 2.09M 1.93M 1.96M
Intangible assets - - - -
Earning assets - - - -
Other current assets 0.04M 0.04M 0.07M 0.05M
Total liab 3.06M 8.15M 3.84M 1.64M
Total stockholder equity 0.23M -6.05580M -1.90959M 0.32M
Deferred long term liab - - - -
Other current liab 0.05M 1.05M 0.00122M 0.00122M
Common stock 0.01M 0.00332M 0.00331M 0.00331M
Capital stock 0.01M 0.00381M 0.00380M 0.00379M
Retained earnings -60.75720M -54.40291M -49.57465M -47.12248M
Other liab 0.19M 0.23M 0.13M -
Good will - - - -
Other assets - - - -
Cash 1.66M 0.92M 0.72M 0.50M
Cash and equivalents - - - -
Total current liabilities 1.83M 3.47M 1.25M 1.14M
Current deferred revenue 0.62M - 0.42M 0.34M
Net debt -0.09460M 5.24M 2.36M 0.45M
Short term debt 0.53M 1.72M 0.49M 0.44M
Short long term debt 0.50M 1.63M 0.38M 0.35M
Short long term debt total 1.57M 6.16M 3.08M 0.94M
Other stockholder equity 61.36M 48.34M 47.66M 47.43M
Property plant equipment 0.59M 0.16M 0.29M 0.42M
Total current assets 2.70M 1.93M 1.64M 1.54M
Long term investments - - - -
Net tangible assets 0.23M -6.05628M -1.91007M 0.32M
Short term investments - - - -
Net receivables 0.32M 0.00232M 0.09M 0.13M
Long term debt 0.50M 4.44M 2.50M 0.30M
Inventory 0.68M 0.67M 0.75M 0.86M
Accounts payable 0.63M 0.69M 0.34M 0.36M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.38100M - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 0.59M 0.16M 0.29M 0.42M
Capital lease obligations 0.57M 0.09M 0.20M 0.29M
Long term debt total - - - -
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Investments -0.01831M -0.00193M -0.00071M 0.00817M
Change to liabilities 0.04M 0.36M -0.02065M -0.30594M
Total cashflows from investing activities -0.01831M -0.00193M -0.00071M 0.00817M
Net borrowings -0.39826M 4.23M 2.48M 0.63M
Total cash from financing activities 6.53M 3.84M 2.68M 1.81M
Change to operating activities 0.14M 0.69M 0.10M -0.03034M
Net income -6.35429M -4.82826M -2.45217M -3.81112M
Change in cash 0.74M 0.19M 0.23M -2.02164M
Begin period cash flow 0.92M 0.72M 0.50M 2.52M
End period cash flow 1.66M 0.92M 0.72M 0.50M
Total cash from operating activities -5.77358M -3.64414M -2.45229M -3.84000M
Issuance of capital stock 5.62M 0.00000M 0.20M 1.18M
Depreciation 0.03M 0.03M 0.03M 0.06M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory -0.00222M 0.08M 0.11M 0.15M
Change to account receivables 0.00232M -0.00232M -0.00232M -0.00700M
Sale purchase of stock - - - -
Other cashflows from financing activities 1.31M -551.42615M -0.00071M 1.83M
Change to netincome 0.32M -0.12391M -0.22386M 0.10M
Capital expenditures 0.02M 0.00193M 0.00071M 0.01M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.17M 1.12M 0.19M -0.19597M
Stock based compensation 0.25M 0.07M 0.02M 0.14M
Other non cash items -100.96749M -0.03559M -0.24854M -0.02179M
Free cash flow -5.79188M -3.64608M -2.45301M -3.85142M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HSCS
Heart Test Laboratories Inc. Common Stock
-0.35 9.31% 3.41 - - 377.16 0.81 53.66 -0.1664
ABT
Abbott Laboratories
1.29 1.15% 113.22 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation
-0.41 0.11% 358.76 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
0.41 0.51% 80.44 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
1.08 1.23% 89.11 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

Profile

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Heart Test Laboratories Inc. Common Stock

550 Reserve Street, Southlake, TX, United States, 76092

Key Executives

Name Title Year Born
Mr. Andrew Simpson CEO, Pres & Chairman of Directors 1969
Ms. Danielle Watson CFO & Treasurer 1982
Mr. Mark T. Hilz COO, Sec. & Director 1959
Mr. Andrew Simpson CEO, President & Chairman of the Board of Directors 1970
Ms. Danielle Watson CFO & Treasurer 1983
Mr. Mark T. Hilz COO, Secretary & Director 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions